Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Welcure Drugs and Pharmaceuticals Ltd

Your Vote -

Buy

66.67%

Hold

22.22%

Sell

11.11%

66.67%

9 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Welcure Drugs and Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Welcure Drugs & - Announcement Pursuant To Regulation 32 Of SEBI (LODR) Regulations, 2015 - Non Applicability Of Filing State

    29 May 2025, 6:01PM Non Applicability of Filing Statement of Deviation/Variation in Utilization of Funds for Quarter and Year Ended 31st March, 2025
  • Welcure Drugs & - Announcement under Regulation 30 (LODR)-Change in Management

    29 May 2025, 5:56PM Appointment of Secretarial Auditor
  • Welcure Drugs & - Audited Standalone Financial Results And Audited Standalone Financial Statements Along With Auditor'S Repor

    29 May 2025, 5:47PM Audited Standalone Financial Results and Audited Standalone Financial Statements along with Auditor's Report of the Company for the quarter and year e
  • Welcure Drugs & - Board Meeting Outcome for Outcome Of Board Meeting

    29 May 2025, 5:32PM Outcome of Board Meeting
  • Welcure Drugs & - Board Meeting Intimation for For Consideration And Approval Of The Audited Financial Results\r\nFor The Qua

    20 May 2025, 4:30PM Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 ,inter alia,
  • Welcure Drugs & - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    15 May 2025, 4:27PM Intimation of Notice of Postal Ballot for E-Voting
  • Welcure Drugs & - Announcement under Regulation 30 (LODR)-Change in Management

    14 May 2025, 4:16PM Appointment of Managing Director
  • Welcure Drugs & - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association

    14 May 2025, 4:13PM Amendments to Memorandum of Association
  • Welcure Drugs & - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Welcure Drugs & Pharmaceutica

    14 May 2025, 4:11PM Outcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited
  • Welcure Drugs & - Board Meeting Intimation for Intimation Of Meeting Of The Board Of Directors Under The Regulation 29 Of The

    9 May 2025, 12:58PM Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2025 ,inter alia,
  • Welcure Drugs & - Announcement under Regulation 30 (LODR)-Change in Management

    6 May 2025, 4:50PM Intimation of Appointment of CFO Pursuant to Regulation 30 of SEBI(LODR) Regulation 2015.
  • Welcure Drugs & - Appointment of Company Secretary and Compliance Officer

    6 May 2025, 4:47PM Intimation of Appointment of Company Secretary & Compliance officer pursuant to Regulation 30 of sebi(LODR) Regulation 2015.
  • Welcure Drugs & - Announcement under Regulation 30 (LODR)-Change in Management

    6 May 2025, 4:43PM Intimation under Regulation 30 of SEBI(LODR) Regulations 2025.
  • Welcure Drugs & - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Welcure Drugs &\r\nPharmaceut

    6 May 2025, 4:40PM Outcome of the Meeting of Board of Directors of Welcure Drugs & Pharmaceuticals Ltd.held on today i.e Tuesday 06th May 2025
  • Welcure Drugs & - Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)

    6 May 2025, 4:33PM Intimation of Resignation of Chief Financial officer under regulation 30 of SEBI(LODR) Regulation 2015\r\n
  • Welcure Drugs & - Announcement under Regulation 30 (LODR)-Resignation of Managing Director

    6 May 2025, 4:31PM Intimation of Resignation of Managing Director under regulation 30 of SEBI(LODR) Regulation 2015
  • Welcure Drugs & has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    15 Apr 2025, 7:01AM As of March 2025, 100.00% owned by Public. <p align=justify>
  • Welcure Drugs & - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    10 Apr 2025, 1:00PM Certificate under Regulation 74(5) of SEBI(Depository and participants)Regulations,2018 for the Quarter and year ended 31st March 2025.

Key fundamentals

Evaluate the intrinsic value of Welcure Drugs and Pharmaceuticals Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 225.7094 1.341 1.5152 0.093 0.0694
Liabilities 225.7094 1.341 1.5152 0.093 0.0694
Equity 112.4391 13.439 13.439 12.1185 12.1186
Gross Profit 0.8778 -0.232 -0.1322 0.0235 0.0549
Net Profit 2.1701 -0.174 0.1017 0.0235 0.0551
Cash From Operating Activities -222.0288 -0.127 0.1068 0.0185 0.0422
NPM(%) 8.83 0 0 22.45 41.33
Revenue 24.55 0 0 0.105 0.1333
Expenses 23.6722 0.232 0.1322 0.0814 0.0784
ROE(%) 2.11 -0.16 0.09 0.02 0.05

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Welcure Drugs and Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 859.90 1.12 28.38 6.22 301.39 0.58
Lotus Eye Hospital and Institute Ltd 72.27 -2.54 205.89 22.67 3.55 0.00
Bharat Immunological and Biologicals Corporation Ltd 26.00 1.13 0.00 47.07 -39.50 0.00
Astec Lifesciences Ltd 806.15 -0.38 0.00 21.37 -687.10 0.00

Company Info

Welcure Drugs and Pharmaceuticals Limited (hereinafter referred to as 'The Company' or 'WDPL') was incorporated as a Public Limited Company under the Companies Act, 1956 on 4th June, 1992 and obtained the certificate of commencement of business on 19th June 1992. The registered office of the Company is situated at E-1052. Saraswati Vihar, Delhi - 110 034. PRESENT BUSINESS Presently, the Company is engaged in the business of manufacture and marketing of pharmaceuticals formulations in the form of tablets, capsules and dry syrups. The Company is manufacturing over hundred varieties of formulations including antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarials, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilisers, sedatives and gastro intestinals. The products of the company have already been well accepted in the domestic markets and the Company has an established customer base. SWOT ANALYSIS Strengths 1. One of the Promoters is having over two decades and the other two promoters are having over a decade experience in the pharmaceutical industry. 2. The Plant & Machinery taken by the company is a multipurpose plant on which other drugs can be produced apart from what company intends to manufacture. 3. The technolgy required to manufacture of the drugs is indegenously available. 4. Approval of first floor of factory by Drugs Control Department to systematically and properly utilise the space for expanded capacity. 5. Major portion of bulk drugs will be used for captive consumption for manufacture of pharmaceuticals formulations. 6. With the completion of the bulk drug unit, the Company will have integrated facilities to manufacture intermediates, bulk drugs and formulations. 7. Subsidiary Company A.K.Laboratories Ltd. is producing 6 APA, a critical drug intermediate used for manufacture of life saving antibiotic drugs like viz. Ampicillin, Amoxycillin, Cloxacillin and Cephalexin. Weaknesses 1. Commercial production of the existing formulation unit was delayed by five months and bulk drug unit is expected to be delayed by approximately 18 months. 2. The cost of the project and means of finance have not been appraised by any Bank/Financial Institution. 3. Delay in Government approvals may affect the timely implementation of the project. Opportunities 1. Products have a growing domestic market and good export potential. Threats 1. Competition from existing and proposed manufacturers as is normal and prevalent in any industry. 2. Changes in Drug Policy announced by the Government from time to time may have an impact on the operations of the Company. 2008 -Welcure Drugs & Pharmaceuticals Ltd has designated E-mail ID for Investors Complaints - welcure@gmail.com.

Welcure Drugs and Pharmaceuticals Limited (hereinafter referred to as 'The Company' or 'WDPL') was incorporated as a Public Limited Company under the Companies Act, 1956 on 4th June, 1992 and obtained the certificate of commencement of business on 19th June 1992. The registered office of the Company is situated at E-1052. Saraswati Vihar, Delhi - 110 034. PRESENT BUSINESS Presently, the Company is engaged in the business of manufacture and marketing of pharmaceuticals formulations in the form of tablets, capsules and dry syrups. The Company is manufacturing over hundred varieties of formulations including antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarials, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilisers, sedatives and gastro intestinals. The products of the company have already been well accepted in the domestic markets and the Company has an established customer base. SWOT ANALYSIS Strengths 1. One of the Promoters is having over two decades and the other two promoters are having over a decade experience in the pharmaceutical industry. 2. The Plant & Machinery taken by the company is a multipurpose plant on which other drugs can be produced apart from what company intends to manufacture. 3. The technolgy required to manufacture of the drugs is indegenously available. 4. Approval of first floor of factory by Drugs Control Department to systematically and properly utilise the space for expanded capacity. 5. Major portion of bulk drugs will be used for captive consumption for manufacture of pharmaceuticals formulations. 6. With the completion of the bulk drug unit, the Company will have integrated facilities to manufacture intermediates, bulk drugs and formulations. 7. Subsidiary Company A.K.Laboratories Ltd. is producing 6 APA, a critical drug intermediate used for manufacture of life saving antibiotic drugs like viz. Ampicillin, Amoxycillin, Cloxacillin and Cephalexin. Weaknesses 1. Commercial production of the existing formulation unit was delayed by five months and bulk drug unit is expected to be delayed by approximately 18 months. 2. The cost of the project and means of finance have not been appraised by any Bank/Financial Institution. 3. Delay in Government approvals may affect the timely implementation of the project. Opportunities 1. Products have a growing domestic market and good export potential. Threats 1. Competition from existing and proposed manufacturers as is normal and prevalent in any industry. 2. Changes in Drug Policy announced by the Government from time to time may have an impact on the operations of the Company. 2008 -Welcure Drugs & Pharmaceuticals Ltd has designated E-mail ID for Investors Complaints - welcure@gmail.com.

Read More

Parent Organisation

Welcure Drugs & Pharmaceuticals Ltd.

Founded

06/08/1996

Managing Director

NSE Symbol

FAQ

The current price of Welcure Drugs and Pharmaceuticals Ltd is

The 52-week high for Welcure Drugs and Pharmaceuticals Ltd is

The market capitalization of Welcure Drugs and Pharmaceuticals Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Welcure Drugs and Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Welcure Drugs and Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Welcure Drugs and Pharmaceuticals Ltd shares.

The CEO of Welcure Drugs and Pharmaceuticals Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT